Vicore Pharma Holding AB
NASDAQ:VCREMedical - Pharmaceuticals
-$0.24 today
- Market cap
- $279.65M
- Beta
- 0.15
Volume 0.00M
Average 0.26M
Income Statement
Follow revenue through to earnings.
Revenue
$3.82M
FY 2025 · Annual
-96.5% YoYOperating Income
-$454.44M
FY 2025 · Annual
Net Income
-$477.47M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 109.35M | 3.82M |
| Cost of Revenue | 3.58M | 0 | 0 | 0 | 0 |
| Gross Profit | (3.58M) | 0 | 0 | 109.35M | 3.82M |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 30.05M | 249.97M | 276.29M | 249.26M | 390.35M |
| Selling, General & Admin | 2.39M | 37.53M | 44.6M | 50.44M | 67.91M |
| Operating Expenses | 32.59M | 290.73M | 321.51M | 299.71M | 458.26M |
| Depreciation & Amortization | 371.33K | 3.61M | 3.42M | 2.24M | 0 |
| EBITDA | (32.07M) | (285.19M) | (307.9M) | (166.64M) | (477.41M) |
| EBITDA Margin | — | — | — | -152.4% | -12507.6% |
| Operating Income | (32.59M) | (290.73M) | (321.51M) | (190.36M) | (454.45M) |
| Operating Margin | — | — | — | -174.1% | -11905.8% |
| Interest Income | 70.2K | 913K | 10.54M | 21.08M | 23.89M |
| Interest Expense | 0 | 8K | 2K | 8K | 60K |
| Other Income / Expenses | (211.92K) | 1.92M | 10.18M | 21.47M | (23.03M) |
| Income Before Tax | (32.8M) | (288.81M) | (311.33M) | (168.89M) | (477.47M) |
| Pre-Tax Margin | — | — | — | -154.5% | -12509.1% |
| Income Tax Expense | (252.7K) | (384K) | (384K) | (256K) | 0 |
| Net Income | (294.97M) | (288.42M) | (310.94M) | (168.63M) | (477.47M) |
| Net Margin | — | — | — | -154.2% | -12509.1% |
| EPS (Basic) | (0.47) | (38.82) | (31.80) | (12.30) | (19.90) |
| EPS (Diluted) | (0.47) | (38.82) | (31.80) | (12.30) | (19.90) |
| 69.68M | 7.42M | 9.66M | 13.68M | 23.99M | |
| 69.68M | 7.42M | 9.66M | 13.68M | 23.99M |
VCRE Earnings Waterfall · TTM
NASDAQ:VCRE · Revenue to Net Income
Key Ratios
Analysis
$1.3M of revenue converted into -$272.5M of net income for the selected period. Gross margin is 100.0% and net margin is -18037.4%, showing how much revenue survives after costs and taxes. EPS is $-9.40, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 5, 2026 | |
| 6-K | 6-K filing | Nov 3, 2026 | |
| 6-K | 6-K filing | Oct 22, 2026 | |
| SC 13G | SC 13G filing | Oct 13, 2026 | |
| 6-K | 6-K filing | Sep 30, 2026 |
How much revenue does VCRE generate?
Vicore Pharma Holding AB (VCRE) reported $3.82M of revenue in fiscal 2025.
Is VCRE profitable?
Vicore Pharma Holding AB (VCRE) reported -$477.47M of net income, with a net margin of -12509.1%.
Continue the stock analysis
Jump to another research area for this company.